Novartis Cracks the BTK Code: Remibrutinib Solves MS Liver Toxicity

BASEL, Switzerland – October 23, 2026 – In the intricate world of pharmaceutical engineering, solving one biological problem often creates another. For the past several years, the race to develop Bruton’s tyrosine kinase (BTK) inhibitors for multiple sclerosis has been a perfect example of this systemic bottleneck. The drugs showed immense promise in halting the progression of the disease by crossing the blood-brain barrier, but they repeatedly failed at a critical hurdle: they were devastatingly toxic to the liver.

Today, Novartis announced it has engineered a way past that barrier. Presenting at the MSToronto2026 medical congress and publishing simultaneously in The Lancet, the Swiss pharmaceutical giant unveiled pivotal Phase III data for remibrutinib, an oral BTK inhibitor that demonstrated superior relapse control in relapsing multiple sclerosis (RMS) without triggering the hepatotoxicity that has plagued the rest of the drug class.

For a disease that affects nearly 3 million people worldwide, the implications of the REMODEL-1 and REMODEL-2 trials represent a massive transition in how we manage chronic neuroinflammation. It signals a shift away from blunt-force immune suppression toward precision immune modulation, fundamentally altering the calculus for patients and clinicians alike.

A Breakthrough for BTK Inhibitors: Solving the Liver Safety Conundrum

To understand the magnitude of the remibrutinib data, one must look at the graveyard of competing BTK inhibitors. The drug class was designed to be a silver bullet for MS, capable of targeting both peripheral B-cell inflammation and the central nervous system's microglia—the cells primarily responsible for the slow, creeping disability progression that characterizes the disease.

But the class quickly ran into a wall of severe drug-induced liver injury (DILI). Sanofi’s tolebrutinib was slapped with a partial clinical hold by the FDA in 2022 and ultimately received a Complete Response Letter in early 2026 after a patient required a liver transplant and subsequently died. Merck KGaA’s evobrutinib faced similar FDA clinical holds for liver toxicity before ultimately failing its efficacy endpoints. Roche’s fenebrutinib also faced FDA holds and reported a case meeting Hy's Law—a rigorous clinical indicator of severe, potentially fatal liver damage.

Novartis appears to have bypassed this systemic failure entirely. In the REMODEL trials, remibrutinib demonstrated no liver safety signals and zero Hy’s Law cases. In fact, patients treated with remibrutinib experienced fewer liver enzyme elevations than those on the active comparator, teriflunomide. Only 2.0% of remibrutinib patients experienced ALT elevations greater than three times the upper limit of normal, compared to 7.4% on teriflunomide. Industry analysts note that the liver profile in the remibrutinib arm is virtually indistinguishable from placebo groups in historical MS trials.

By designing a highly selective, covalent molecule, Novartis managed to isolate the therapeutic mechanism of BTK inhibition from the off-target toxicity that derailed its competitors. It is a triumph of molecular engineering that essentially rescues an entire modality of treatment.

Beyond B-Cell Depletion: The Next Generation of Oral MS Therapy

While the safety profile is the headline for regulators and investors, the efficacy data is what will change patient lives. The REMODEL-1 and REMODEL-2 trials, which enrolled approximately 2,000 patients globally, met their primary endpoints with commanding statistical significance.

Remibrutinib reduced the annualized relapse rate by 35.2% and 31.2% relative to teriflunomide across the two trials. In practical terms, this translates to a patient experiencing approximately one relapse every 13 years. Furthermore, the drug achieved a nominally significant 29.2% risk reduction in 6-month confirmed disability progression. Over 92% of patients receiving the drug remained entirely free from disease progression over 24 months.

“The REMODEL trial results showed that oral remibrutinib delivered a significant reduction in relapse activity while also showing a clinically meaningful effect on confirmed disability progression in people living with relapsing MS,” said Prof. Dr. Heinz Wiendl, Chair of the Department of Neurology and Neurophysiology at the Medical Center, University of Freiburg. “As treatment goals in MS continue to evolve beyond relapse control alone, these efficacy findings, together with the favorable safety profile, suggest remibrutinib has the potential to deliver a meaningful, differentiated treatment option.”

The systemic shift here lies in the mechanism of action. The current high-efficacy standards of care—anti-CD20 monoclonal antibodies like Kesimpta and Ocrevus—work by aggressively depleting the body's B-cells. While highly effective at stopping relapses, this chronic depletion leaves patients immunocompromised and vulnerable to infections. Remibrutinib, conversely, is a B-cell modulator. It blocks the activation pathways of B-cells and innate immune cells without wiping them out entirely.

Coupled with its ability to significantly reduce disease activity in the brain—cutting active inflammatory MRI lesions by 66%—remibrutinib offers the high efficacy of an infusion therapy with the convenience and immunological safety of a daily pill.

Strengthening a Neurology Fortress: Commercial Implications

For Novartis, remibrutinib is not just a scientific victory; it is a vital commercial pillar. The company already commands a massive share of the MS market with Kesimpta, its injectable anti-CD20 therapy. By adding a best-in-class oral BTK inhibitor to its portfolio, Novartis is effectively building a fortress around its neuroscience franchise.

The strategic positioning is clear. Clinicians who prefer the aggressive B-cell depletion of an injectable can utilize Kesimpta, while patients seeking a highly effective daily oral medication that preserves overall immune function can be prescribed remibrutinib.

“Novartis has a two-decade legacy developing therapies in multiple sclerosis and continues to advance innovation for people living with the disease,” said Shreeram Aradhye, President, Development, and Chief Medical Officer at Novartis. “By combining high efficacy with a favorable safety profile through a selective mechanism, remibrutinib has the potential to support long-term disease management without chronic B-cell depletion and to redefine what may be possible across the MS journey.”

The drug is already a known entity to global regulators. Under the brand name Rhapsido, remibrutinib secured FDA and EMA approvals in 2025 and 2026 for chronic spontaneous urticaria and symptomatic dermographism. This existing commercial footprint in dermatology provides a vast, real-world safety database that will likely smooth its transition into the neurology market.

The Regulatory Horizon

Novartis plans to file for global regulatory approvals for remibrutinib in RMS based on these REMODEL results. Given the FDA’s recent, highly publicized rejection of Sanofi’s tolebrutinib, regulatory agencies will undoubtedly subject remibrutinib’s liver data to microscopic scrutiny. However, the sheer distance between remibrutinib’s pristine safety profile and the fatal DILI cases seen in rival programs suggests a highly favorable path to approval.

If cleared by the FDA and EMA without the burdensome boxed warnings or onerous biweekly liver monitoring requirements that crippled its predecessors, remibrutinib will enter the market with a distinct competitive advantage.

In the broader context of medical progress, the success of remibrutinib is a testament to the value of iterative, systems-level problem solving in pharmacology. Where others saw an insurmountable class-wide toxicity issue, Novartis engineered a precise molecular bypass. The result is a therapy that promises to keep the central nervous system intact without sacrificing the liver, offering millions of patients a safer, simpler way to maintain control over their lives.